Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) EPS (Weighted Average and Diluted) (2019 - 2025)

Harmony Biosciences Holdings' EPS (Weighted Average and Diluted) history spans 7 years, with the latest figure at $0.38 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 55.29% year-over-year to $0.38; the TTM value through Dec 2025 reached $2.71, up 7.97%, while the annual FY2025 figure was $2.71, 7.97% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.38 at Harmony Biosciences Holdings, down from $0.87 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.44 in Q3 2022 and bottomed at -$0.17 in Q3 2021.
  • The 5-year median for EPS (Weighted Average and Diluted) is $0.52 (2023), against an average of $0.55.
  • The largest annual shift saw EPS (Weighted Average and Diluted) plummeted 77.25% in 2021 before it soared 947.06% in 2022.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.38 in 2021, then surged by 107.89% to $0.79 in 2022, then tumbled by 41.77% to $0.46 in 2023, then skyrocketed by 84.78% to $0.85 in 2024, then crashed by 55.29% to $0.38 in 2025.
  • Per Business Quant, the three most recent readings for HRMY's EPS (Weighted Average and Diluted) are $0.38 (Q4 2025), $0.87 (Q3 2025), and $0.68 (Q2 2025).